A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors

• Autores: Stuti Fernandes, Elena V. Varlamov, Shirley McCartney, Maria Fleseriu
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 49, Nº. 3, 2020 (Ejemplar dedicado a: Pituitary Disorders), págs. 387-399
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Immune checkpoint inhibitor (ICPi) therapy used in cancer treatment exerts effect by blocking the actions of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1).1,2 These ICPi drugs have revolutionized oncology and improved survival in patients with advanced melanoma, non–small cell lung cancer, renal cell carcinoma, colorectal, and other cancers